Drug intelligence / Profile preview

VAR 400

Development stage: Preclinical
Lead developer: Variant Pharmaceuticals

Overview

VAR 400 is an investigational drug candidate developed by Variant Pharmaceuticals. It is part of the company's renal pipeline, which is undergoing clinical development. Incon has secured exclusive negotiation rights for the commercialization of Variant's renal pipeline, including VAR 400, in certain Asian countries.

Beyond the preview

Go deeper on VAR 400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VAR 400.

Explore the full profile